|
Written by IOMSN Administrator
|
|
Tuesday, 04 October 2011 14:20 |
|
| DATE POSTED |
T I T L E / A N N O U N C E M E N T
|
| April 2012 |
Novartis Announces Update to GilenyaTM (fingolimod) U.S. Prescribing Information Following FDA Review
Novartis Press Release: click here
Gilenya Prescribing Information (PDF: 427KB)
In addition, on April 20, 2012, the European Medicines Agency (EMA) issued a press release outlining changes to the recommended use of Gilenya in the European Union (Summary of Product Characteristics). These recommendations do not apply to the U.S.
EMA Press Release: click here
Summary of Product Characteristics (PDF: 384KB)
|
| March 2012 |
THE JANET PEARCE MS NURSE TRAINING PROGRAM
March 23 and 24, 2012 (Friday and Saturday)
The NYU Wasserman Center for Career Development
133 East 13th St. (between 3rd and 4th Avenues), 2/F
New York, N.Y. 10003
8:30 a.m. – 4:30 p.m. (both days)
This is the eighth conference of the Janet Pearce MS Nurse Training Program which began 10 years ago. For more information contact Andrea Arzt at 212-453-3215 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
View Complete Program Information
|
| March 2012 |
THE 4TH ANNUAL LINDA MORGANTE MS NURSE LEADERSHIP PROGRAM
This intensive, two-day course on contemporary topics in MS is led by faculty who are thought leaders in MS nursing. The program will be held Monday through Wednesday, May 28-30, 2012 at the Hilton San Diego Bayfront, immediately preceding the CMSC Annual Meeting in San Diego, California.
To apply for the program you must be a nurse with an interest in MS who is based in the United States or Canada. Please complete the application to apply for the program.
Space is limited to 40 nurses, apply by March 9, 2012! Please contact Katie at 877-444-8435 ext. 159 or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
if you have any questions.
View Complete Program Information
|
|
|
Last Updated on Thursday, 13 September 2012 20:19 |
